Company news

Disc Medicine, Inc. news in 2024

Disc Medicine, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

December 8, 2024

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

December 7, 2024

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

November 7, 2024

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

November 4, 2024

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

November 3, 2024

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

October 31, 2024

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

October 24, 2024

Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

October 22, 2024

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

October 10, 2024

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

September 18, 2024

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

June 13, 2024

Disc Medicine Announces Underwritten Offering of Common Stock

June 13, 2024

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

May 13, 2024

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

May 12, 2024

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

March 31, 2024

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 20, 2024

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

March 5, 2024

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

February 25, 2024

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

February 19, 2024

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

February 8, 2024

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

February 6, 2024

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Decks in 2024